Table 1.

Summary of Morphological Data and Results of COX Enzyme Histochemistry and Immunohistochemistry in Human Kidney Biopsies.

Patient No.	IFTA	Global Sclerosis (%)	PT Hypertrophy (%), Atrophy (%), Normal (%)	Creatinine (mg%)	Clinical Diagnosis	PT COX Activity (1–4)a	PT COX IV IHC (1–4)a
1	Mild	Minimal	Regeneration	11.3	HIV–tenofovir–AKI	2, 3, 4	2, 3, 4
2	Mild	Minimal	40, 15, 45	1.8	Hepatitis B, adefovir	2, 3	2, 3
3	Mild	Minimal	0, 0, 100	0.8	Minimal amyloidosis	2	2
4	Mild	Minimal	20, 0, 80	1.2	SLE class III	3, 4	2
5	Mild	Minimal	0, 0, 100	0.7	SLE class III	3, 4	2
6	Mild	Minimal	0, 0, 100	0.6	SLE class IV	3, 4	2
7	Mild	Minimal	50, 30, 20	4	CAN	2, 3, 4	2, 3, 4
8	Mild	Minimal	80, 10, 10	3.2	Posttransplant—AKI	2, 3, 4	3, 4
9	Mild to moderate	Minimal	30, 10, 60	4.4	CAN	2, 3, 4	2, 3, 4
10	Moderate	Minimal	70, 30, 0	3.5	CAN	2, 3, 4	3, 4
11	Moderate	50–70	70, 30, 0	1.7	CAN	2, 3, 4	2, 3, 4
12	Mild to moderate	Minimal	70, 30, 0	3.1	Drug-associated interstitial nephritis + DM	2, 3	2, 3
13	Moderate	Minimal	85, 25, 0	3.4	Drug-associated interstitial nephritis	1, 2, 3	2, 3, 4
14	Moderate to severe	50	60, 40, 0	4	DM + HTN	2, 3, 4	2, 3, 4
15	Severe	60	70, 30, 0	8.6	ANCA-associated vasculitis	2, 3, 4	2, 3, 4
16	Severe	40	25, 85, 0	11	Advanced CAN	1, 2, 3, 4	1, 2, 3, 4
17	Severe	90	25, 85, 0	4.2	Advanced CAN	1, 2, 3, 4	1, 2, 3, 4
18	Severe	40	30, 70, 0	6.1	Severe HTN—CKD ANCA-type glomerulonephritis	1, 2, 3, 4	1, 2, 3, 4
19	Severe	40	30, 70, 0	2	Morbidly obese, HTN, nondiabetic	1, 2, 3, 4	1, 2, 3, 4
20	Severe	60	30, 70, 0	2.8	ESRD	1, 2, 3, 4	2, 3, 4

Abbreviations: IFTA, interstitial fibrosis and tubular atrophy; PT, proximal tubular; COX, cytochrome C oxidase; IHC, immunohistochemistry; AKI, acute kidney injury; SLE, systemic lupus erythematosus; CAN, chronic allograft nephropathy; DM, diabetes mellitus; HTN, hypertensive nephropathy; ANCA, antineutrophil cytoplasmic antibodies; CKD, chronic kidney disease; ESRD, end-stage renal disease.

^aThese numbers (1–4) illustrate the variation of grades in a given biopsy.